<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2930">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519320</url>
  </required_header>
  <id_info>
    <org_study_id>2020/499</org_study_id>
    <nct_id>NCT04519320</nct_id>
  </id_info>
  <brief_title>Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae</brief_title>
  <acronym>COV-RECUP</acronym>
  <official_title>Medium and Long Term Follow-up of SARS-COV-2 Infected Patients Treated at Besançon and Dijon Hospitals: Research and Characterization of Pulmonary Sequelae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of atypical&#xD;
      emerging pneumonia. The clinical spectrum varies from an asymptomatic or mild illness to a&#xD;
      serious illness with a high risk of mortality. The most severely affected patients (5%)&#xD;
      present an acute respiratory distress syndrome (ARDS), requiring assistance with mechanical&#xD;
      ventilation in intensive care.&#xD;
&#xD;
      In 2003, persistent lung damage was observed in a third of patients in a Singaporean cohort&#xD;
      one year after SARS-CoV infection. A Chinese study showed that 27.3% of their SARS-CoV&#xD;
      patients presented a decreased carbon monoxide diffusion (DLCO) and 21.5% of pulmonary&#xD;
      fibrosis lesions.&#xD;
&#xD;
      Due to the very recent emergence of SARS-CoV-2, no data is currently available of long-term&#xD;
      outcome of these patients. However, recent publications including short-term CT monitoring&#xD;
      suggest the genesis of fibrotic pulmonary parenchymal sequelae.&#xD;
&#xD;
      In view of these data, the investigators can fear the occurrence of pulmonary sequelae in&#xD;
      patients infected with SARS-CoV-2. It is therefore essential to evaluate the evolution of the&#xD;
      respiratory status of the most severe patients who have had a stay in intensive care with&#xD;
      respiratory assistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">August 18, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with an alteration of the capillary alveolus barrier at 12 months of follow-up, characterized by a decreased of the diffusing capacity for carbon monoxide (DLCO) below the lower limit of normal</measure>
    <time_frame>12 months after the first symptoms of SARS-COV-2</time_frame>
    <description>DLCO</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>SARS-COV 2 Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pulmonary function testing</intervention_name>
    <description>D0: date of first symptoms of SARS-COV-2&#xD;
M3: D0 + 3 months&#xD;
Blood test&#xD;
Blood gases&#xD;
Clinical examination&#xD;
CT Scan&#xD;
Pulmonary function testing (PFT)&#xD;
6-minute walk test (6MWT)&#xD;
MOS SF-36 Questionnaire&#xD;
HADS scale&#xD;
Ventilatory polygraphy&#xD;
M6: D0 + 6 months&#xD;
Clinical examination&#xD;
PFT&#xD;
6MWT&#xD;
MOS SF-36 Questionnaire&#xD;
HADS scale&#xD;
M12: D0 + 12 months&#xD;
Blood test&#xD;
Blood gases&#xD;
Clinical examination&#xD;
CT Scan (If anomaly found at M3)&#xD;
PFT&#xD;
Pulmonary Exercise Stress Test&#xD;
6MWT&#xD;
MOS SF-36 Questionnaire&#xD;
HADS scale&#xD;
Subsequent follow-up will be performed only in patients with an alteration defined by a DLCO &lt;LLN and / or an abnormality objectified at CT-Scan attributable to SARS-CoV-2.&#xD;
M24, M36, M48 and M60: D0 + 24, 36, 48, 60 months&#xD;
Clinical examination&#xD;
PFT&#xD;
6MWT&#xD;
MOS SF-36 Questionnaire&#xD;
HADS scale</description>
    <arm_group_label>SARS-COV 2 Patients</arm_group_label>
    <other_name>CT Scan</other_name>
    <other_name>Six minute walk test</other_name>
    <other_name>Pulmonary Exercise Stress Test</other_name>
    <other_name>Blood gases</other_name>
    <other_name>Ventilatory polygraphy</other_name>
    <other_name>Questionnaires: HADS and MOS SF-36</other_name>
    <other_name>Blood Test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient infected by SARS-CoV-2 (diagnosed by RT-PCR and / or typical CT imaging)&#xD;
&#xD;
          -  Patient hospitalized in the intensive care units of Besançon or Dijon hospitals for&#xD;
             severe SARS-CoV-2 pneumonia&#xD;
&#xD;
          -  Postmenopausal woman for at least 24 months or surgically sterilized, or, for woman of&#xD;
             childbearing age, use of an effective method of contraception&#xD;
&#xD;
          -  Signature of informed consent to participate indicating that the subject has&#xD;
             understood the purpose and the procedures required by the study and that he agrees to&#xD;
             participate in the study.&#xD;
&#xD;
          -  Affiliation to a French social security system .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic respiratory failure under long-term oxygen therapy&#xD;
&#xD;
          -  Known diffuse invasive pneumonia&#xD;
&#xD;
          -  Life expectancy estimated at less than one year by the doctor&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  History of psychiatric illness, intellectual disability, lack of motivation or other&#xD;
             conditions that may limit the understanding of informed consent&#xD;
&#xD;
          -  Subject unlikely to cooperate in the study and / or weak cooperation anticipated by&#xD;
             the investigator&#xD;
&#xD;
          -  Subject without health insurance&#xD;
&#xD;
          -  Pregnant and / or lactating woman&#xD;
&#xD;
          -  Subject being in the exclusion period of another study or foreseen by the &quot;national&#xD;
             file of the volunteers&quot;.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guillaume Eberst, PH</last_name>
    <phone>03.81.66.88.02</phone>
    <email>geberst@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucie Laurent, PhD</last_name>
    <phone>03.81.66.92.93</phone>
    <email>llaurent@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <state>Franche-Comté</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eberst Guillaume, PH</last_name>
      <phone>0381668802</phone>
      <email>geberst@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

